Baloxavir marboxil is a novel, oral, antiviral agent approved by the Food and Drug Administration (FDA) on Oct. 24, 2018, for the treatment of acute uncomplicated influenza in patients 12 years of age and older.
A multicenter, retrospective, cohort study from southern and eastern Europe identified predictive factors for multidrug-resistant complicated urinary tract infections (cUTI), which included male sex, cUTI acquisition in a healthcare facility, presence of a Foley catheter, having a UTI in the previous year, and receiving an antibiotic in the preceding 30 days.
A randomized, open-label, superiority trial found that daily antibiotic prophylaxis for patients who use clean, intermittent self-catheterization reduced symptomatic urinary tract infections by 48% over a 12-month period. Antibiotic resistance became prevalent in urinary isolates from the group receiving prophylaxis compared to controls.
In a recently released study, Centers for Disease Control and Prevention (CDC) researchers report that while 81% of patients diagnosed with gonorrhea were treated using dual therapy, nearly one in five were treated with a different regimen.